Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm to Acquire Products or Companies

Published: Saturday, March 08, 2014
Last Updated: Saturday, March 08, 2014
Bookmark and Share
Company to expand activities at manufacturing facility in Martigny (Valais, Switzerland).

Debiopharm Group™ (Debiopharm) has announced its decision to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its industrial development and production facility in Martigny (Valais, Switzerland), through acquisition of industrial high value added activities or companies in the pharmaceutical, biotech or medtech field.

Debiopharm Research & Manufacturing S.A. boasts 35 years of expertise in drug development including chemical synthesis, formulation improvement and manufacturing. Major investments have been made since 2007 to automate the facility and increase its industrial capacity.

The objective is to expand industrial operations in Martigny by acquiring opportunities for optimization and production, generating a double-digit million revenue annually.

Expertise in R&D and manufacturing of hard-to-make pharmaceutical products, modern infrastructure combined with high tech GMP-compliant production, a logistic platform for worldwide delivery, established quality assurance and regulatory certification, as well as a central location in Europe are some of the features that will enable this objective to be met.

"We want to be the bridge between development and industrialization" says Cédric Sager, Chief Executive Officer of Debiopharm Research & Manufacturing S.A. "and supply Swiss-made products manufactured using state-of-the-art technology. Hard-to-make drugs, highly complex formulated drugs, biologic niche products, premium diagnostics and medical devices are on our wish-list".

Thierry Mauvernay, Delegate of the Board of Debiopharm Group, explains that "we have invested heavily during the last years to automate our site in Martigny as much as possible. Thanks to our efforts, we have increased our productivity. Our wish now is to acquire new industrial opportunities to strengthen our activity in Valais and support our development".


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Debiopharm Acquires FibroTrap Sample Processing Technology from Spinomix
FibroTrap improves sensitivity and shortens time taken from sample collection to results.
Saturday, June 20, 2015
Scientific News
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!